Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: Preliminary report

Senji Hoshi, Chikara Ohyama, Kunio Ono, Atsushi Takeda, Shinichi Yamashita, Takashi Yamato, Akihiro Itoh, Makoto Satoh, Seiichi Saito, Yasuhiro Okada, Fumihiko Sohma, Yoichi Arai

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Abstract

Background. The aim of this study was to evaluate the efficacy and safety of two combined chemotherapy regimens in the treatment of previously treated metastatic urothelial carcinoma: gemcitabine plus carboplatin (GC), and gemcitabine, docetaxel, and carboplatin (GDC). Methods. Sixteen patients with metastatic urothelial cancer, previously treated with a platinum-based regimen, were studied. GC (gemcitabine 750 mg/m2, on days 1, 8, and 15; carboplatin 200 mg/m2, on day 2) was administered every 28 days to 15 patients. GDC (gemcitabine 750 mg/m2, on days 1 and 8; docetaxel 50 mg/m2, on day 1; carboplatin 200 mg/m2 on day 1) was administered every 21 days to 9 patients. Eight of the 9 GDC-treated patients had earlier been treated with GC and had become refractory. Results. With the GC therapy, 7 of the 15 treated patients (47%; 95% confidence interval, 21%-73%) showed an objective response, with 3 achieving a clinical complete response (CR) and 4 a partial response (PR). With the GDC therapy, 6 of the 9 treated patients (67%; 95% confidence interval, 29%-92%) showed an objective response, with 1 achieving CR and 5, PR. Five of the 8 (63%) GC-refractory patients responded to GDC therapy. The median duration of response was 4 months (range, 2-10+ months) on GC therapy, and 3 months (range, 3-5 months) on GDC therapy. Toxicities associated with GC were less than those with GDC. Conclusion. GC was effective for refractory metastatic urothelial cancer, and GDC was effective for GC-refractory cancer.

Original languageEnglish
Pages (from-to)125-129
Number of pages5
JournalInternational Journal of Clinical Oncology
Volume9
Issue number2
DOIs
Publication statusPublished - 2004 Apr

Keywords

  • Docetaxel
  • Gemcitabine
  • Metastatic urothelial cancer

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: Preliminary report'. Together they form a unique fingerprint.

Cite this